REGN9933 for Preventing Blood Clots After Knee Surgery
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing REGN9933, a new medication, to see if it can prevent blood clots in patients having knee replacement surgery. The medication works by stopping clots from forming in the blood vessels.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Who Is on the Research Team?
Clinical Trial Management
Principal Investigator
Regeneron Pharmaceuticals
Are You a Good Fit for This Trial?
Adults in good health needing knee replacement surgery can join this trial. They should weigh no more than 130 kg and have stable vital signs, normal ECG, and lab tests. People with recent bleeding issues, thromboembolic disease, major surgeries or trauma within the last 6 months, or severe kidney problems cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive REGN9933 or comparator drugs (enoxaparin or apixaban) for prevention of VTE after knee arthroplasty
Follow-up
Participants are monitored for safety, efficacy, and immunogenicity of REGN9933
What Are the Treatments Tested in This Trial?
Interventions
- REGN9933
Find a Clinic Near You
Who Is Running the Clinical Trial?
Regeneron Pharmaceuticals
Lead Sponsor
Leonard Schleifer
Regeneron Pharmaceuticals
Chief Executive Officer since 1988
MD and PhD in Medicine
George Yancopoulos
Regeneron Pharmaceuticals
Chief Medical Officer since 1997
MD from Harvard Medical School